Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer

被引：8
作者：
Lu, Jun [1 ,2 ,3 ,4 ]
Zhang, Wei [1 ]
Yu, Keke [4 ]
Zhang, Lele [1 ]
Lou, Yuqing [1 ]
Gu, Ping [1 ]
Nie, Wei [1 ]
Qian, Jie [5 ]
Xu, Jun [6 ]
Wang, Huimin [1 ]
Zhong, Hua [1 ]
Han, Baohui [1 ,2 ,3 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Sch Med, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Inst Thorac Oncol, Sch Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Translat Med Res Platform Thorac Oncol, Sch Med, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Dept Biobank, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Dept Emergency Med, Sch Med, Shanghai Chest Hosp, Shanghai, Peoples R China
[6] Anhui Med Univ, Dept Emergency Med, Hosp 1, Hefei, Peoples R China
来源：
FASEB JOURNAL | 2022年 / 36卷 / 08期
关键词：
anlotinib; biomarker; liquid biopsy; non-small cell lung cancer; proteomics; EXTRACELLULAR VESICLES; NSCLC; 3RD;
D O I：
10.1096/fj.202101658R
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The response stratification of anlotinib remains unclear. In this study, plasma samples from 28 anlotinib-treated NSCLC patients (discovery cohort: 14 responders and 14 non-responders) were subjected to proteomic analysis, and plasma samples from 35 anlotinib-treated NSCLC patients (validation cohort) were subjected to validation analysis. Liquid chromatography-tandem mass spectrometry analysis was performed on samples with different time points, namely baseline (BL), best response (BR), and progression disease (PD). Bioinformatics analysis was performed to screen for the underlying differential proteins. Enzyme-linked immunosorbent assay was performed to detect plasma ARHGDIB, FN1, CDH1, and KNG1 levels respectively. The Kaplan-Meier survival analysis was used for biomarker-based responsive stratification. Our results indicated that differential proteins between responders and non-responders showed that proteomic technology potentially contributes to biomarker screening in plasma samples at BL. Furthermore, our results suggested that the detection of plasma ARHGDIB, FN1, CDH1, and KNG1 levels have potential predictive value for anlotinib response both in the discovery cohort and validation cohort. Collectively, this study offers novel insights into the value of plasma biomarker screening via proteomic examination and suggests that plasma ARHGDIB, FN1, CDH1, and KNG1 levels could be used as biomarkers for anlotinib stratification in NSCLC patients.
引用
收藏
页数：14
相关论文
共 37 条
[1]   Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection [J].
Barnabas, Georgina D. ;
Bahar-Shany, Keren ;
Sapoznik, Stav ;
Helpman, Limor ;
Kadan, Yfat ;
Beiner, Mario ;
Weitzner, Omer ;
Arbib, Nissim ;
Korach, Jacob ;
Perri, Tamar ;
Katz, Guy ;
Blecher, Anna ;
Brandt, Benny ;
Friedman, Eitan ;
Stockheim, David ;
Jakobson-Setton, Ariella ;
Eitan, Ram ;
Armon, Shunit ;
Brand, Hadar ;
Zadok, Oranit ;
Aviel-Ronen, Sarit ;
Harel, Michal ;
Geiger, Tamar ;
Levanon, Keren .
MOLECULAR & CELLULAR PROTEOMICS, 2019, 18 (05) :865-875
[2]   Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates [J].
Boccellino, Mariarosaria ;
Pinto, Federica ;
Ieluzzi, Vincenzo ;
Giovane, Alfonso ;
Quagliuolo, Lucio ;
Fariello, Chiara ;
Coppola, Mario ;
Carlucci, Annalisa ;
Santini, Mario ;
Ferati, Kenan ;
Bexheti-Ferati, Arberesha ;
Giordano, Antonio ;
Di Domenico, Marina .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (12) :23798-23806
[3]  
Cheng Y., 2019, ANN ONCOL, V30, pv711
[4]   Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma [J].
Chi, Yihebali ;
Fang, Zhiwei ;
Hong, Xiaonan ;
Yao, Yang ;
Sun, Ping ;
Wang, Guowen ;
Du, Feng ;
Sun, Yongkun ;
Wu, Qiong ;
Qu, Guofan ;
Wang, Shusen ;
Song, Jianmin ;
Yu, Jianchun ;
Lu, Yongkui ;
Zhu, Xia ;
Niu, Xiaohui ;
He, Zhiyong ;
Wang, Jinwan ;
Yu, Hao ;
Cai, Jianqiang .
CLINICAL CANCER RESEARCH, 2018, 24 (21) :5233-5238
[5]   Direct observation of mineral-organic composite formation reveals occlusion mechanism [J].
Cho, Kang Rae ;
Kim, Yi-Yeoun ;
Yang, Pengcheng ;
Cai, Wei ;
Pan, Haihua ;
Kulak, Alexander N. ;
Lau, Jolene L. ;
Kulshreshtha, Prashant ;
Armes, Steven P. ;
Meldrum, Fiona C. ;
De Yoreo, James J. .
NATURE COMMUNICATIONS, 2016, 7
[6]   Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial [J].
Chu, Tianqing ;
Lu, Jun ;
Bi, Minghong ;
Zhang, Helong ;
Zhuang, Wu ;
Yu, Yan ;
Shi, Jianhua ;
Chen, Zhendong ;
Zhang, Xiaochun ;
Guo, Qisen ;
Liu, Quan ;
Wu, Huijuan ;
Fang, Jian ;
Hu, Yi ;
Wang, Xiuwen ;
Han, Cuicui ;
Li, Kai ;
Han, Baohui .
CANCER BIOLOGY & MEDICINE, 2021, 18 (03) :816-+
[7]   Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts [J].
Eckert, Mark A. ;
Coscia, Fabian ;
Chryplewicz, Agnieszka ;
Chang, Jae Won ;
Hernandez, Kyle M. ;
Pan, Shawn ;
Tienda, Samantha M. ;
Nahotko, Dominik A. ;
Li, Gang ;
Blazenovic, Ivana ;
Lastra, Ricardo R. ;
Curtis, Marion ;
Yamada, S. Diane ;
Perets, Ruth ;
McGregor, Stephanie M. ;
Andrade, Jorge ;
Fiehn, Oliver ;
Moellering, Raymond E. ;
Mann, Matthias ;
Lengyel, Ernst .
NATURE, 2019, 569 (7758) :723-+
[8]   Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer [J].
Fujita, Kazutoshi ;
Kume, Hideaki ;
Matsuzaki, Kyosuke ;
Kawashima, Atsunari ;
Ujike, Takeshi ;
Nagahara, Akira ;
Uemura, Motohide ;
Miyagawa, Yasushi ;
Tomonaga, Takeshi ;
Nonomura, Norio .
SCIENTIFIC REPORTS, 2017, 7
[9]   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial [J].
Han, Baohui ;
Li, Kai ;
Wang, Qiming ;
Zhang, Li ;
Shi, Jianhua ;
Wang, Zhehai ;
Cheng, Ying ;
He, Jianxing ;
Shi, Yuankai ;
Zhao, Yizhuo ;
Yu, Hao ;
Zhao, Yang ;
Chen, Weiqiang ;
Luo, Yi ;
Wu, Lin ;
Wang, Xiuwen ;
Pirker, Robert ;
Nan, Kejun ;
Jin, Faguang ;
Dong, Jian ;
Li, Baolan ;
Sun, Yan .
JAMA ONCOLOGY, 2018, 4 (11) :1569-1575
[10]   Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) [J].
Han, Baohui ;
Li, Kai ;
Zhao, Yizhuo ;
Li, Baolan ;
Cheng, Ying ;
Zhou, Jianying ;
Lu, You ;
Shi, Yuankai ;
Wang, Zhehai ;
Jiang, Liyan ;
Luo, Yi ;
Zhang, Yiping ;
Huang, Cheng ;
Li, Qiang ;
Wu, Guoming .
BRITISH JOURNAL OF CANCER, 2018, 118 (05) :654-661
1234